Trial Profile
The Prospective Non-randomized Phase II Clinical Trial of Vemurafenib in Combination With Cytarabine and 2-chlorodeoxyadenosine in Children With Langerhans-cell Hisitocytosis With BRAF V600E Mutation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Vemurafenib (Primary)
- Indications Langerhans cell histiocytosis
- Focus Therapeutic Use
- 15 Mar 2023 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 15 Mar 2023 Planned primary completion date changed from 1 Mar 2021 to 1 Apr 2023.
- 06 Apr 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.